静脉对比剂暴露前预防性干预预防对比剂肾病的系统综述与Meta分析
该系统综述与Meta分析纳入22项研究,评估成人静脉注射碘对比剂前预防性干预对对比剂肾病(CIN)的疗效。与生理盐水对照组相比,N-乙酰半胱氨酸(NAC)可降低CIN发生率(风险差=-0.07,95%CI -0.13至-0.01),而碳酸氢钠与生理盐水对照组相比未降低CIN发生率(风险差=-0.02,95%CI -0.04至0.01)。已发表研究未提示预防性干预对肾脏替代治疗需求、死亡率或持续性肾功能损害有显著影响。
要点
- NAC组较生理盐水对照组CIN发生率降低(风险差=-0.07,95%CI -0.13至-0.01)。
- 碳酸氢钠组较生理盐水对照组CIN发生率无显著差异(风险差=-0.02,95%CI -0.04至0.01)。
- 预防性干预对肾脏替代治疗需求、死亡率或持续性肾功能损害无显著影响。
核心结论
- 静脉碘对比剂暴露前预防CIN的证据有限;NAC使用与静脉对比剂后CIN发生率降低相关,但对其他评估的临床结局无影响,这些发现的临床意义尚不明确,需要针对这些临床结局进一步研究。
研究设计与样本
- 系统综述与随机效应Meta分析,纳入22项评估多种预防性干预的研究进行定性分析;检索已发表的同行评议文章,并手动审查既往系统综述和National Institute for Health and Care Excellence指南的参考文献;使用Cochrane协作组偏倚风险评估工具评估偏倚风险。
诊断标准与关键数值
- NAC组较生理盐水对照组CIN发生率降低(风险差=-0.07,95%CI -0.13至-0.01)。
- 碳酸氢钠组较生理盐水对照组CIN发生率无显著差异(风险差=-0.02,95%CI -0.04至0.01)。
- 已发表研究未提示预防性干预对肾脏替代治疗需求、死亡率或持续性肾功能损害有显著影响。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 静脉碘对比剂暴露前预防CIN的证据有限。
- NAC使用与CIN发生率降低相关,但对其他评估的临床结局无影响,这些发现的临床意义尚不明确。
- 需要针对这些临床结局进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Iodinated radiographic contrast media has been associated with an acute deterioration in renal function, termed contrast induced nephropathy (CIN). This review aims to establish the efficacy of prophylaxis interventions used in adult patients prior to intravenous exposure to iodinated contrast to reduce the risk of CIN.
METHODS: An electronic search for published peer-reviewed articles was performed, supplemented with manual review of references from previous systematic reviews and the National Institute for Health and Care Excellence guidelines. Risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of bias. Random-effect meta-analyses were used to assess CIN incidence, need for kidney replacement therapy (KRT), mortality, fluid overload and persistent kidney dysfunction.
RESULTS: 22 studies assessing a range of interventions were included in the qualitative analysis. The incidence of CIN was reduced by the use of N-acetylcysteine compared to a control group of saline (risk difference = -0.07, 95% CI -0.13 to -0.01) but not by sodium bicarbonate compared to control group of saline (risk difference = -0.02, 95% CI -0.04 to 0.01). Published studies give no indication that prophylactic interventions have significant impact on the need for KRT, mortality or persistent renal impairment.
CONCLUSION: Evidence for prophylaxis against CIN in patients receiving intravenous iodinated contrast is limited. There was an association with the use of NAC with reduced incidence of CIN following intravenous contrast but there was no impact on other clinical outcomes assessed. The clinical significance of these findings remains unclear and further research focusing on these clinical outcomes is required.
引用
- Walker, Guthrie, Lambourg, et al. Systematic review and meta-analysis of prophylaxis use with intravenous contrast exposure to prevent contrast-induced nephropathy. Eur J Radiol. 2022. PMID: 35636024. doi:10.1016/j.ejrad.2022.110368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。